期刊文献+

新的4′-去甲表鬼臼衍生物的合成及其抗癌活性 被引量:4

Synthesis and Anti-cancer Activity of Novel Derivatives of 4′-Demethylepipodophyllotoxin
下载PDF
导出
摘要 根据鬼臼毒衍生物和 5 氟尿嘧啶的抗癌机理和构效关系 ,合成了 7个新的 4β 5 氟尿嘧啶取代 4′ 去甲表鬼臼毒衍生物 .在抑制金属基质蛋白酶I和胶原酶I活性测试中 ,化合物 2 .4和 2 .6的抑制活性比鬼臼乙叉甙 (VP 16 )和5 氟尿嘧啶 (5 Fu)强 3倍和 5倍 ,在治疗癌细胞转移方面值得进一步探讨 . According to the structure-activity relationship of podophyllotoxin derivatives, along with the different anti-cancer mechanism between demethylepipodophyllotoxin and 5-fluorouracil seven novel 4beta-5-fluorouracil substituted 4'-demethylepipodophyllotoxin derivatives were synthesized and evaluated as inhibitors of stromelysin-1 as well as collagenase-1. Among them, compounds 2. 4 and 2. 6 exhibited superior inhibitor activity against stromelysin-1 than that of prototype drugs, etoposide and 5-fluorouracil (inhibitory ratio were 80.2, 80.0, 25.5 and 15.8 for compounds 2.4, 2.6, etoposide and 5-Fu, respectively).
作者 张辅民 田瑄
出处 《化学学报》 SCIE CAS CSCD 北大核心 2002年第4期720-724,共5页 Acta Chimica Sinica
基金 甘肃省自然科学基金 (ZS0 0 1 A2 3 0 5 2 Y)资助项目
关键词 4′-去甲表鬼臼衍生物 合成 抗癌活性 5-氟尿嘧啶 鬼臼毒素 抗癌药物 5-fluorouracil podophyllotoxin synthesis anti-cancer activity
  • 相关文献

参考文献2

二级参考文献25

  • 1[24]Pavlovsky AG, Williams MG, Ye QZ, et al. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity [J]. Protein Sci, 1999, 8(7): 1455 - 1462.
  • 2[25]Pikul S, McDow-Dunham KL, Almstead NG, et al. Discovery of potent, achiral matrix metalloproteinase inhibitors [J]. JMed Chem, 1998, 41(19):3568-3571.
  • 3[1]Johnson LL, Dyer R, Hupe DJ, et al. Matrix metalloproteinases[J]. Curr Opin Chem Biol, 1998, 2(4):466 -471.
  • 4[2]Babine RE, Bender SL. Molecular recognition of proteinligand complexes: applications to drug design[ J]. Chem Rev, 1997, 97(5): 1359 - 1472.
  • 5[3]Bottomley KM, Johnson WH, Walter DS. MMPs inhibitors in arthritis[J]. J Enzyme Inhib, 1998, 13(2) :79- 101.
  • 6[4]Suzuki D. Metalloproteinases in the pathogenesis of diabetic nephropathy[J]. Nephron, 1998, 80(2): 125 - 133.
  • 7[5]Wojtowicz-Praga SM, Dickson RB, Hawkins MJ, et al.Matrix metalloproteinase inhibitors[ J]. Invest New Drugs,1997, 15(1):61-75.
  • 8[6]Brown PD. MMPs inhibitors[J]. Breast Cancer Res Treat,1998, 52(1/3): 125 - 136.
  • 9[7]Dhanara JV, Ye QZ, Johnson LL, et al. Designing inhibitors of the metalloproteinase superfamily: comparative analysis of representative structures[J]. Drug Des Discov,1996, 13(3/4) :3- 14.
  • 10[8]Kiyama R, Tamura Y, Watanabe F, et al. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors[J]. J Med Chem, 1999, 42(10): 1723 - 1738.

共引文献17

同被引文献81

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部